Complement Therapeutics

Complement is developing therapeutics that are aimed at systemic modulation of the complement system to address unmet needs in a range of diseases related to complement dysregulation.

Complement’s lead asset CTx001 is currently in pre-clinical development as an AAV based gene therapy for the treatment of Geographic Atrophy (late dry age-related macular degeneration).

Alan O Connell.

Managed by

Alan O'Connell


We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top